KRAS G12C

KRAS G12C: what it means for you

Does your report say KRAS G12C? Here is what this change is, how common it is and which medicines exist.

  • 3 min read
  • Updated 17 November 2026

Most important in brief

  • KRAS G12C is a change in the tumour’s genes. It is usually not inherited.
  • About 1 in 7 people with NSCLC have it.
  • Two tablets for KRAS G12C are authorised in the EU: sotorasib and adagrasib, after a first treatment.
  • Ask your oncologist whether they are available and covered in your country.

What does KRAS G12C mean?

Every cell has genes, a kind of instruction set. The KRAS gene helps control when a cell grows and divides. You can think of it as a switch.

“G12C” names one specific change (mutation) in this gene. It can leave the switch stuck on “grow”. The change happens in the tumour itself. It is usually not inherited and is not passed on to your children.

Without the change

on, then off again

KRAS gives the “grow” signal only briefly, then switches off again. The cell grows only when it should.

With KRAS G12C

stays on

Because of the change, the switch gets stuck on “grow”. The tumour cells keep getting the signal to divide.

Medicines for KRAS G12C are designed to block exactly this stuck switch. More below. Simplified picture.

Why does it matter? There are now medicines aimed specifically at tumours with KRAS G12C. Whether and when they are right for you is decided by your care team. Read more below.

How common is it?

In a large international registry (AACR Project GENIE), about 14 in every 100 NSCLC samples had the KRAS G12C change, 13.8 percent to be exact (Nassar et al., NEJM 2021).

Worldwide, there were an estimated 2.48 million new cases of lung cancer in 2022 (Bray et al., 2024).

Medicines for KRAS G12C

Two substances aimed at KRAS G12C are authorised in the EU: sotorasib and adagrasib.

Both are authorised for advanced NSCLC with KRAS G12C after an earlier treatment that works throughout the body. So in the EU they are usually not the first treatment.

Whether they are available and paid for differs from country to country. Ask your oncologist.

More details on the authorisation

Sotorasib has had a conditional authorisation since 6 January 2022, last renewed on 10 November 2025 (EMA).

Adagrasib has had a conditional authorisation since 5 January 2024, renewed on 17 November 2025 (EMA).

“Conditional authorisation” means: the benefits outweigh the risks, but more data are still expected.

This page does not rank one substance above the other.

When the medicines for KRAS G12C come into play

In advanced NSCLC with KRAS G12C, the first treatment is usually immunotherapy, often together with chemotherapy, as for tumours without a first-line targeted treatment. The tablets for KRAS G12C come afterwards in the EU, in the second line (ESMO).

Trials are testing whether they help earlier, for example together with immunotherapy (review). Ask your care team whether a trial could be right for you.

Questions about KRAS G12C

  • Why ask?

    A second change can alter which treatment fits best.

  • Why ask?

    In the EU these tablets are authorised after a first treatment.

  • Why ask?

    Newer medicines are not on every health insurance list.

  • Why ask?

    Newer KRAS inhibitors are being tested, including earlier in treatment.

Sources

  1. Nassar et al., New England Journal of Medicine 2021
  2. Bray et al., CA: A Cancer Journal for Clinicians 2024; GLOBOCAN / IARC
  3. ESMO Living Guideline: oncogene-addicted metastatic NSCLC
  4. EMA: EPAR sotorasib
  5. EMA: EPAR adagrasib
  6. Therapeutic strategies for KRAS G12C-mutant NSCLC (review, PubMed Central)

All sources last checked on 12 November 2026, unless another date is given.